{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:13:42Z","timestamp":1781136822820,"version":"3.54.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,3,28]],"date-time":"2017-03-28T00:00:00Z","timestamp":1490659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1038\/bjc.2017.67","type":"journal-article","created":{"date-parts":[[2017,3,28]],"date-time":"2017-03-28T20:02:41Z","timestamp":1490731361000},"page":"1247-1253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Quality-adjusted survival with combination nal-IRI+5-FU\/LV vs 5-FU\/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis"],"prefix":"10.1038","volume":"116","author":[{"given":"Uwe","family":"Pelzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fr\u00e9d\u00e9ric","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Melisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cubillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D","family":"Von Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Wang-Gillam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Tzong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens T","family":"Siveke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlyn T","family":"Solem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc F","family":"Botteman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoojung","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floris A","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A","family":"Hubner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,28]]},"reference":[{"key":"BFbjc201767_CR1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1200\/jco.2015.33.3_suppl.234","volume":"33","author":"L-T Chen","year":"2015","unstructured":"Chen L-T, Von Hoff DD, Li C-P, Wang-Gillam A, Bodoky G, Dean AP, Shan Y-S, Jameson GS, Macarulla T, Lee K-H (2015) Expanded analyses of napoli-1: phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy. J Clin Oncol 33: 234.","journal-title":"J Clin Oncol"},{"key":"BFbjc201767_CR2","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1002\/sim.4780141606","volume":"14","author":"BF Cole","year":"1995","unstructured":"Cole BF, Gelber RD (1995) A quality-adjusted survival meta-analysis of adjuvant chemotherapy for premenopausal breast cancer. Stat Med 14: 1771\u20131784.","journal-title":"Stat Med"},{"key":"BFbjc201767_CR3","doi-asserted-by":"publisher","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","volume":"26","author":"M Ducreux","year":"2015","unstructured":"Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Go\u00e9r\u00e9 D, Seufferlein T, Haustermans K, Van Laethem J, Conroy T (2015) Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26: v56\u2013v68.","journal-title":"Ann Oncol"},{"key":"BFbjc201767_CR4","doi-asserted-by":"crossref","DOI":"10.1201\/9781420061185","volume-title":"Design and Analysis of Quality of Life Studies in Clinical Trials","author":"DL Fairclough","year":"2010","unstructured":"Fairclough DL (2010) Design and Analysis of Quality of Life Studies in Clinical Trials. CRC Press."},{"issue":"6","key":"BFbjc201767_CR5","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","volume":"49","author":"J Ferlay","year":"2013","unstructured":"Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49 (6): 1374\u20131403.","journal-title":"Eur J Cancer"},{"key":"BFbjc201767_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0305-7372(93)90060-5","volume":"19","author":"RD Gelber","year":"1993","unstructured":"Gelber RD, Goldhirsch A, Cole BF Group IBCS (1993) Evaluation of effectiveness: Q-TWiST. Cancer Treat Rev 19: 73\u201384.","journal-title":"Cancer Treat Rev"},{"key":"BFbjc201767_CR7","first-page":"178","volume":"2014","author":"D Goldstein","year":"2014","unstructured":"Goldstein D, Maraghi E, Hassan R, Hammel P, Heinemann V, Kunzmann V, Sastre J, Scheithauer W, Siena S, Tabernero J (2014) Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas. ASCO Annu Meeting Proc 2014: 178.","journal-title":"ASCO Annu Meeting Proc"},{"key":"BFbjc201767_CR8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457\u2013481.","journal-title":"J Am Stat Assoc"},{"key":"BFbjc201767_CR9","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/sj.bjc.6603326","volume":"95","author":"A Lloyd","year":"2006","unstructured":"Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J (2006) Health state utilities for metastatic breast cancer. BJC 95: 683\u2013690.","journal-title":"BJC"},{"key":"BFbjc201767_CR10","doi-asserted-by":"publisher","first-page":"6660","DOI":"10.2174\/1381612820666140826154327","volume":"20","author":"D Melisi","year":"2014","unstructured":"Melisi D, Calvetti L, Frizziero M, Tortora G (2014) Pancreatic cancer: systemic combination therapies for a heterogeneous disease. Curr Pharm Des 20: 6660\u20136669.","journal-title":"Curr Pharm Des"},{"key":"BFbjc201767_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7525-6-84","volume":"6","author":"B Nafees","year":"2008","unstructured":"Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J (2008) Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 6: 1.","journal-title":"Health Qual Life Outcomes"},{"key":"BFbjc201767_CR12","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","volume":"32","author":"H Oettle","year":"2015","unstructured":"Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, G\u00f6rner M, M\u00f6lle M, Greten TF, Lakner V, Bischoff S, Sinn M, D\u00f6rken B, Pelzer U (2015) Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 32: 2423\u20132429.","journal-title":"J Clin Oncol"},{"key":"BFbjc201767_CR13","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74: 2913\u20132921.","journal-title":"Cancer Res"},{"key":"BFbjc201767_CR14","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3111\/13696998.2014.903122","volume":"17","author":"M Reni","year":"2014","unstructured":"Reni M, Wan Y, Solem C, Whiting S, Ji X, Botteman M (2014) Quality-adjusted survival with combination nab-paclitaxel+ gemcitabine vs gemcitabine alone in metastatic pancreatic cancer: a Q-TWiST analysis. J Med Econ 17: 338\u2013346.","journal-title":"J Med Econ"},{"key":"BFbjc201767_CR15","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s11136-005-1579-7","volume":"15","author":"DA Revicki","year":"2006","unstructured":"Revicki DA, Feeny D, Hunt TL, Cole BF (2006) Analyzing oncology clinical trial data using the Q-TWiST method: clinical importance and sources for health state preference data. Qual Life Res 15: 411\u2013423.","journal-title":"Qual Life Res"},{"key":"BFbjc201767_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jpainsymman.2011.09.001","volume":"43","author":"D Romanus","year":"2012","unstructured":"Romanus D, Kindler HL, Archer L, Basch E, Niedzwiecki D, Weeks J, Schrag D, Cancer BLG (2012) Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage 43: 205\u2013217.","journal-title":"J Pain Symptom Manage"},{"key":"BFbjc201767_CR17","doi-asserted-by":"publisher","first-page":"A194","DOI":"10.1016\/j.jval.2014.03.1135","volume":"17","author":"C Solem","year":"2014","unstructured":"Solem C, Wan Y, Botteman M (2014) Systematic review of the Q-TWiST in oncology. Value Health 17: A194\u2013A195.","journal-title":"Value Health"},{"key":"BFbjc201767_CR18","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1185\/03007991003712258","volume":"26","author":"P Swinburn","year":"2010","unstructured":"Swinburn P, Lloyd A, Nathan P, Choueiri TK, Cella D, Neary MP (2010) Elicitation of health state utilities in metastatic renal cell carcinoma. Curr Med Res Opin 26: 1091\u20131096.","journal-title":"Curr Med Res Opin"},{"key":"BFbjc201767_CR19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3389\/fphar.2013.00056","volume":"4","author":"A Tamburrino","year":"2013","unstructured":"Tamburrino A, Piro G, Carbone C, Tortora G, Melisi D (2013) Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. Front Pharmacol 4: 56.","journal-title":"Front Pharmacol"},{"key":"BFbjc201767_CR20","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.6004\/jnccn.2014.0106","volume":"12","author":"MA Tempero","year":"2014","unstructured":"Tempero MA, Malafa MP, Behrman SW, Benson AB, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A (2014) Pancreatic adenocarcinoma, version 2.2014. J Natl Compr Canc Netw 12: 1083\u20131093.","journal-title":"J Natl Compr Canc Netw"},{"key":"BFbjc201767_CR21","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s10198-012-0419-2","volume":"14","author":"K Tolley","year":"2013","unstructured":"Tolley K, Goad C, Yi Y, Maroudas P, Haiderali A, Thompson G (2013) Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia. Eur J Health Econ 14: 749\u2013759.","journal-title":"Eur J Health Econ"},{"key":"BFbjc201767_CR22","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam A, Li C-P, Bodoky G, Dean A, Shan Y-S, Jameson G, Macarulla T, Lee K-H, Cunningham D, Blanc JF (2016) Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387: 545\u2013557.","journal-title":"Lancet"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc201767.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201767","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bjc.2017.67","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201767.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:41:34Z","timestamp":1684417294000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc201767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,28]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["BFbjc201767"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2017.67","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,28]]},"assertion":[{"value":"8 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"UP has no disclosures. J-FB has received honoraria for lectures and consultancy and travel grants from Amgen, Bayer, Celgene, Merck, Roche and Sanofi-Aventis. J-FB has had a consultant or advisory role at Merck, Amgen, and Lilly. DM is a consultant for Lilly, and has received travel, accommodations, or expenses from Lilly and Celgene. AC has no disclosures. DDVH is employed by McKesson, and has had a consultant or advisory role at Arsia Therapeutics, Bionomics, Bristol-Myers Squibb, Cavion, Cerulean Pharma, CytRX Corporation, Dalian Wanchun Biotechnology, DNAtrix, Esperance Pharmaceuticals, Five Prime Therapeutics, Formula Pharmaceuticals, HealthCare Pharmaceuticals, Ignyta, Imaging Endpoints, Immodulon Therapeutics, Inform Genomics, Insys Therapeutics, Lilly, Medelis, Medical Prognosis Institute, Merus, miRNA Therapeutics, NuCana BioMed, Oncolytics Biotech, Pain Therapeutics, Pharmacyclics, Samumed, Senhwa Biosciences, Superlab Far East, Theravance, Tolero Pharmaceuticals, Toray Industries, Trovagene, Alethia Biotherapeutics, Alpha Cancer Technologies, Arvinas. Bellicum Pharmaceuticals, Biological Dynamics, CanBas, Horizon Discovery, Innate Pharma, Kinex, Lixte Biotechnology, MBC Pharma, Oncolyze, RenovoRx, Samsung, TD2, AADi, Aptose Biosciences, BiolineRx, CV6 Therapeutics, CytomX Therapeutics, Deciphera, EMD Serono, Evelo Therapeutics, Fujifilm, Gilead Sciences, Histogen, Horizon Pharma, Idera, Intezyne Technologies, Kalos Therapeutics, Kura, Lantern Pharma, Pain Therapeutics, Pfizer, Pharmamab, Phosplatin Therapeutics, Progen, SOTIO, Strategia Therapeutics, Sun Biopharma, Systems Imagination, Ventana Medical Systems. DDVH has received travel, accommodations, or expenses from FORMA Therapeutics and Merrimack. DDVH\u2019s patents, royalties, and other intellectual property include: intramedullary catheter, methods of human prostate cancer, use of 5,6-dihydro-5-azacytidine in the treatment of prostate cancer, targeting site-2 protease (S2P) for the treatment of pancreatic cancer (pending), targeting ecto-5-nucleotidase (CD73) for the treatment of pancreatic cancer, targeting a protein tyrosine phosphotase-PRL-1 for the treatment of pancreatic cancer (pending), targeting a protein PRC1 for the treatment of pancreatic cancer (pending), protein kinase inhibitors (pending), methods, compounds and compositions with genotype selective anticancer activity (pending), methods and kits to predict therapeutic outcome of BTK inhibitors (pending), muscle fatigue substance cytokines and methods of inhibiting tumour growth therewith (pending), 2-arylpyridylazoles for the treatment of solid tumours such as pancreatic cancer (pending). DDVH has stock or ownership interests in cell therapeutics, McKesson, Medtronic, CerRx, EmergingMed, and SynDevRx. DDVH has received honoraria from Celgene, Cerulean Pharma, and Genentech. DDVH\u2019s institution has received research funding from Lilly, Genentech, Celgene, Agios, Incyte, Merrimack, Plexxikon, Minneamrita Therapeutics, 3-V Biosciences, Abbvie, Aduro Biotech, ArQule, Baxalta, Biomarin, Cleave Biosciences, CytRx Corporation, Daiichi Sankyo, Deciphera, Endocyte, Exelixis, ESSA, Five Prime Therapeutics, Gilead Sciences, Merck, miRNA Therapeutics, Pfizer, Pharmacyclics, Phoenix Biotech, Proderm IQ, Sammumed, Strategia, Trovagene, and Verastem. AW-G has had a consultant or advisory role at Merrimack and Pfizer. AW-G has received travel, accommodations, or expenses from Axis Pharma. AW-G received honoraria from Pfizer and Merrimack. AW-G\u2019s institution has received research funding from Newlink Genetics, Precision Therapeutics, AstraZeneca, Merrimack, Aduro Biotech, Prometheus, EMD Serono, Pfizer, Halozyme, OncoMed, and CTI. L-TC received honoraria from and has had a consulting or advisory role at PharmaEngine and Merrimack. JTS has had a consulting or advisory role at Merrimack, Lilly, Amcure, Baxalta (now Shire), and Celgene. JTS has received research funding from Novartis, Boehringer Ingelheim, and Celgene. YW is employed by Pharmerit. YW\u2019s institution has received consulting or advisory role and research funding from Baxalta (now Shire) and numerous other sponsors from the pharmaceutical industry. CTS is employed by Pharmerit. CTS\u2019s institution has received consulting or advisory role and research funding from Baxalta (now Shire) and numerous other sponsors from the pharmaceutical industry. MFB is employed by Pharmerit, and has stock or ownership interests in Pharmerit. MFB\u2019s institution has received consulting or advisory role and research funding from Baxalta (now Shire) and numerous other sponsors from the pharmaceutical industry. YY is employed by Baxalta (now Shire) and has stock or ownership interests in Baxalta (now Shire). FAdJ is employed by Baxalta (now Shire) and has stock or ownership interests in Baxalta (now Shire). RAH has had a consulting or advisory role with BTG and Celgene.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}